Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
Sivapalan P, Moberg M, Eklöf J, Janner J, Vestbo J, Laub RR, Browatzki A, Armbruster K, Wilcke JT, Seersholm N, Weinreich UM, Titlestad IL, Andreassen HF, Ulrik CS, Bødtger U, Nielsen TL, Hansen EF, Jensen JUS. Sivapalan P, et al. Among authors: titlestad il. BMC Pulm Med. 2017 Aug 15;17(1):114. doi: 10.1186/s12890-017-0458-7. BMC Pulm Med. 2017. PMID: 28810909 Free PMC article. Clinical Trial.
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial.
Eklöf J, Alispahic IA, Sivapalan P, Wilcke T, Seersholm N, Armbruster K, Kjærgaard JL, Saeed MI, Nielsen TL, Browatzki A, Overgaard RH, Fenlev CS, Harboe ZB, Andreassen HF, Lapperre TS, Pedersen L, Johnsen S, Ulrik CS, Janner J, Moberg M, Heidemann M, Weinreich UM, Vijdea R, Linde H, Titlestad I, Johansson SL, Rosenvinge FS, Østergaard C, Ghathian KSA, Gundersen L, Christensen CW, Bangsborg J, Jensen TT, Sørensen VM, Ellingsgaard T, Datcu R, Coia JE, Bodtger U, Jensen JUS. Eklöf J, et al. Trials. 2022 Sep 27;23(1):817. doi: 10.1186/s13063-022-06720-z. Trials. 2022. PMID: 36167555 Free PMC article. Clinical Trial.
[Medical treatment of COPD].
Vestbo J, Titlestad IL. Vestbo J, et al. Among authors: titlestad il. Ugeskr Laeger. 2013 Apr 29;175(18):1261-4. Ugeskr Laeger. 2013. PMID: 23651802 Review. Danish.
Authors’ reply.
Titlestad IL, Lassen AT, Vestbo J. Titlestad IL, et al. Int J Chron Obstruct Pulmon Dis. 2013;8:381. Int J Chron Obstruct Pulmon Dis. 2013. PMID: 24137821 No abstract available.
Increased serum SP-D in identification of high-risk smokers at high risk of COPD.
Dalgård C, Wang F, Titlestad IL, Kyvik KO, Vestbo J, Sorensen GL. Dalgård C, et al. Among authors: titlestad il. Am J Physiol Lung Cell Mol Physiol. 2021 Jun 1;320(6):L1005-L1010. doi: 10.1152/ajplung.00604.2020. Epub 2021 Mar 24. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 33759571 Free article.
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE; MESOS study investigators. Russell RJ, et al. Among authors: titlestad il. Lancet Respir Med. 2018 Jul;6(7):499-510. doi: 10.1016/S2213-2600(18)30201-7. Epub 2018 May 21. Lancet Respir Med. 2018. PMID: 29793857 Clinical Trial.
47 results